Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combination Therapy to Prevent Cardiovascular Disease

Combination Therapy to Prevent Cardiovascular Disease VIEWPOINT ONLINE FIRST Combination Therapy to Prevent Cardiovascular Disease Slow Progress 6 randomized trials have shown that the combination of sev- Richard Smith, MB, ChB, MSc, FRCPE eral antihypertensive agents, a statin, and aspirin can sub- Tara McCready, MBA, PhD stantially reduce blood pressure and lipid levels and, when Salim Yusuf, DPhil, FRCPC, FRSC aspirin is included, inhibit platelet aggregation. The pills are well tolerated and have low rates of adverse effects and ARDIOVASCULAR DISEASE IS THE MAJOR CAUSE OF discontinuation. The trials have shown high adherence, al- mortality and morbidity globally and affects half though most have been of short duration. However, a re- of all individuals over their lifetimes. The bur- cent large trial analyzing patients from 12 to 18 months Cden of cardiovascular disease in developing coun- showed that compared with usual care and separate drugs, tries is increasing substantially, and cardiovascular disease combination pills produced a greater reduction in blood pres- 1 6 is becoming the leading cause of death. The concept of com- sure and lipid levels. bining antihypertensive drugs, a statin, and aspirin into a However, none of the trials as yet has included clinical single, fixed-dose, combination pill to prevent myocardial outcomes, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Combination Therapy to Prevent Cardiovascular Disease

JAMA , Volume 309 (15) – Apr 17, 2013

Loading next page...
 
/lp/american-medical-association/combination-therapy-to-prevent-cardiovascular-disease-OWygSWpQAN
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.3180
pmid
23529576
Publisher site
See Article on Publisher Site

Abstract

VIEWPOINT ONLINE FIRST Combination Therapy to Prevent Cardiovascular Disease Slow Progress 6 randomized trials have shown that the combination of sev- Richard Smith, MB, ChB, MSc, FRCPE eral antihypertensive agents, a statin, and aspirin can sub- Tara McCready, MBA, PhD stantially reduce blood pressure and lipid levels and, when Salim Yusuf, DPhil, FRCPC, FRSC aspirin is included, inhibit platelet aggregation. The pills are well tolerated and have low rates of adverse effects and ARDIOVASCULAR DISEASE IS THE MAJOR CAUSE OF discontinuation. The trials have shown high adherence, al- mortality and morbidity globally and affects half though most have been of short duration. However, a re- of all individuals over their lifetimes. The bur- cent large trial analyzing patients from 12 to 18 months Cden of cardiovascular disease in developing coun- showed that compared with usual care and separate drugs, tries is increasing substantially, and cardiovascular disease combination pills produced a greater reduction in blood pres- 1 6 is becoming the leading cause of death. The concept of com- sure and lipid levels. bining antihypertensive drugs, a statin, and aspirin into a However, none of the trials as yet has included clinical single, fixed-dose, combination pill to prevent myocardial outcomes,

Journal

JAMAAmerican Medical Association

Published: Apr 17, 2013

References